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 〔目的〕  
  TNF-related apoptosis-inducing ligand (TRAIL), the member of TNF superfamily of 
cytokines， is a trimeric protein that induces apoptosis in many human cancer cells 
through the binding at two species of trimeric cell surface receptors, TRAIL-R1 and 
TRAIL-R2. TRAIL-R1 and R2 are effective as therapeutic targets by means of TRAIL 
variant and their monoclonal antibodies.  
  Recently our group has generated several TRAIL-R1 human monoclonal antibodies 
by a combination of immunospot array assay on a chip and human antibody-producing 
mice. However, these TRAIL-R1-specific antibodies (TR1-IgGs) did not show ideal 
apoptosis-inducing ability without additional antibodies. Under this context, we tried to 
develop an antibody that induces apoptosis in cancer cells without using additional 
antibodies.  
 〔方法並びに成績〕  
  We pentamerized the TRAIL-R1-specific antibodies by converting IgG to IgM that 
might facilitate the cell surface receptor cross-linking due to its high valency. We 
constructed TRAIL-R1-specific IgM (TR1-IgM) cDNAs by combining the variable 
region of TR1-IgG with the constant region of human IgM. The expressed and purified 
TR1-IgMs were proved to specifically bind TRAIL-R1 expressing cells by flow 
cytometry. In vitro experiments implied that the TR1-IgM were potent inducer of the 
apoptosis in human tumor cell lines and showed much more anti-tumor efficacy than 
TRAIL. Notably, the activation of the caspase-3, a representative cellular response of 
apoptosis, has been observed in cancer cells after treating them with TR1-IgMs. We 
further demonstrated that these TR1-IgMs dramatically inhibited tumor growth in a 
xenograft model through the caspase activation cascade. 
 〔総括〕  
In this study, we generated TRAIL-R1-IgM antibodies (TR1-IgMs) by combining 
the variable region of TR1-IgGs with the constant region of IgM. The resulting 
TR1-IgMs induced strong apoptosis in not only various human cancer cell lines but 
also xenograft tumor-bearing mice. These TR1-IgMs antibodies may become potential 
immunotherapeutic agents for cancer therapy. 
 
 
 
 
 
